Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.60 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | FGR | P09769 | 1/20 | 0.51 |
| ▸ | TEC | P42680 | 1/20 | 0.51 |
| ▸ | BMX | P51813 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1724381 | 0.94 | BTK (0.66) | BTKCLK2YES1FGRTEC | |
| SCHEMBL1726776 | 0.90 | BTK (0.71) | BTKYES1FGRTECBMX | |
| SCHEMBL1726617 | 0.90 | BTK (0.81) | BTKCLK2YES1FGRTEC | |
| SCHEMBL13139703 | 0.86 | BTK (0.56) | BTKCLK2YES1FGRTEC | |
| SCHEMBL3216807 | 0.85 | BTK (0.68) | BTKYES1FGRTECBMX | |
| SCHEMBL3220037 | 0.84 | BTK (0.77) | BTKCLK2 | |
| SCHEMBL1726871 | 0.83 | BTK (0.81) | BTKYES1FGRTECBMX | |
| SCHEMBL3869783 | 0.83 | BTK (0.82) | BTKCLK2 | |
| SCHEMBL1725205 | 0.83 | BTK (0.73) | BTKCLK2YES1FGRTEC | |
| SCHEMBL1725009 | 0.82 | BTK (0.82) | BTKCLK2YES1FGRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906509-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | claimed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | claimed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | KENNEDY-SMITH JOSHUA | 2010-04-22 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885YES1 1140/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | BTK 2508/4885CLK2 4397/4885YES1 877/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885YES1 1140/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | BTK 2508/4885CLK2 4397/4885YES1 877/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | BTK 2478/4885CLK2 4520/4885YES1 1047/4885 |
| US-20100099659-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | BTK 1/4885CLK2 575/4885YES1 17/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | BTK 1276/4885CLK2 3341/4885YES1 1140/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885CLK2 575/4885YES1 17/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | BTK 2478/4885CLK2 4520/4885YES1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.